Home | NRI | Business Associates | Knowledge Bank | Careers | Back Office | Contact Us
 
 
Prospectus synopsis
 
Nephrocare Health Services Ltd
Registered Office: 5th Flr D Block iLabs Centre , Plot 18 Software Units Sy.#.64 , Hyderabad - 500081 , Telangana , India.
Phone:+91 40 4240 8039   Fax:
Email: cs@nephroplus.com   Website:www.nephroplus.com
Initial public offering of 18,943,020 equity shares of face value of Rs.2/- each ("equity shares") of Nephrocare Health Services Limited ("the company" or the "company" or the "issuer") for cash at a price of Rs.460/- per equity share face value of Rs.2/- (including a securities premium of Rs.458/- per equity share) ("offer price") aggregating to Rs.871.05 crores ("offer") comprising a fresh issue of 7,690,162 equity shares of face value of Rs.2/- each aggregating to Rs.353.41 crores ("fresh issue") and an offer for sale of 11,253,102 equity shares of face value of Rs.2/- each ("offered shares") aggregating to Rs.517.64 crores , comprising an offer for sale of 1,521,728 equity shares of face value of Rs.2/- each aggregating to Rs.70.00 crores by Investcorp Private Equity Fund II and 1,604,907 equity shares of face value of Rs.2/- each aggregating to Rs.73.83 crores by Healthcare Parent Limited and 147,765 equity shares of face value of Rs.2/- each aggregating to Rs.6.80 crores by Investcorp Growth Opportunity Fund and 2,888,911 equity shares of face value of Rs.2/- each aggregating to Rs.132.89 crores by Edoras Investment Holdings Pte. Ltd. ("promoter selling shareholders") and 121,985 equity shares of face value of Rs.2/- each aggregating to Rs.5.61 crores by Investcorp India Private Equity Opportunity Limited and 3,089,663 equity shares of face value of Rs.2/- each aggregating to Rs.142.12 crores by International Finance Coproration and 1,433,468 equity shares of face value of Rs.2/- each aggregating to Rs.65.94 crores by 360 One Special Opportunities Fund - Series 9 and 444,675 equity shares of face value of Rs.2/- each aggregating to Rs.20.46 crores by 360 One Special Opportunities Fund - Series 10 ("other selling shareholders" and together with the promoter selling shareholders, the "selling shareholders" and such offer for sale by the selling shareholders, the "offer for sale"). The offer constituted 18.88% of the post-offer paid-up equity share capital of the company.

Issue
Money Payable On
Opens On
Closes On
Application
Allotment
10-Dec-25 12-Dec-25 Rs 460.00-0.00 Rs 0.00-0.00
Minimum Application for shares in Nos : 32   Further Multiples of : 32


 
Rs Cr
Lead Managers to the Issue
Project Cost 325.15
Ambit Private Limited
ICICI Securities Limited
IIFL Capital Services Limited
Nomura Financial Advisory & Securities (I) Pvt Ltd
Project Financed through Current Offer 871.05  
Post Issue Equity Share Capital 20.07  
Issue Price Rs.460.00  
 
Projects
Capital expenditure by our Company for opening new dialysis clinics in India Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company
General corporate purposes
Promoted By
Listing At
Registrar to the Issue
 
 < Back Top
BSE Disclaimer     |     Disclaimer     |     Privacy Statement     |     Terms of Use     |     Feedback     |    Sitemap     |    Downloads    |     Client Bank Details
Useful Links   | Risk Disclosure   | Rules and Regulations   |   Investor Charter / Complaints   |   Smart ODR   |   Scores   |   Attention Investors   | Audit Compliance Report   | RA – Annual Compliance Audit Report 2024-25   | UPI IDs for Payment

SEBI Saa₹thi Mobile App/SEBI Investor Website  

SSJ FINANCE & SECURITIES PRIVATE LIMITED:
1st Floor, Merchant Chamber, Opp. Patkar Hall, 41, New Marine Lines, Mumbai – 400 020
SEBI Regn. Number: INZ000178436 | CDSL: IN-DP-109-2015 | ARN: 40860 | CIN: U67120MH1996PTC104822
SSJ COMMODITIES PRIVATE LIMITED:
SEBI Regn. Number: INZ000013439 | CIN: U51909MH2003PTC140481|Research Analyst SEBI Reg. No.INH000001527
2006-07 © SSJ Finance & Securities Pvt. Ltd. All Rights Reserved Designed, Developed & Maintained By
C-MOTS InfoTech(ISO 9001:2015 & ISO/IEC 27001:2022 Certified)
Content powered by Capital Market Charts are powered by TradingView